Answers are grounded in this paper and cite their sources.
Background: Targeted protein degradation has evolved from a chemical-biology concept into a clinically actionable therapeutic strategy. Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that recruit an E3 ubiquitin ligase to a protein of interest, inducing ubiquitination and proteasomal elimination rather than relying solely on sustained target occupancy. Vepdegestrant, an oral cereblon-recruiting PROTAC directed against estrogen receptor (ER) alpha, provided the first regulatory validation of this approach when the US Food and Drug Administration (FDA) approved it on May 1, 2026 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression following at least one line of endocrine therapy. Summary: In the phase III VERITAC-2 trial, vepdegestrant significantly prolonged progression-free survival (PFS) compared with fulvestrant in the prespecified ESR1-mutated population (median 5.0 vs 2.1 months; hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.43–0.78), whereas the difference in the overall randomized population was not statistically significant (3.8 vs 3.6 months; HR 0.83, 95% CI 0.69–1.01). These findings establish clinically effective targeted protein degradation while defining an important biological boundary: the demonstrated benefit is concentrated in ESR1-mutated disease. The approval also occurs within a rapidly changing therapeutic landscape that includes elacestrant, imlunestrant, and ctDNA-guided early switching to camizestrant after molecular detection of emerging ESR1 mutations. In this narrative review, we examine the mechanistic foundations of PROTAC pharmacology, the preclinical and clinical development of vepdegestrant, the strengths and limitations of VERITAC-2, practical pharmacologic considerations, emerging resistance mechanisms, and the implications of targeted protein degradation for biomarker-guided endocrine therapy and oncology more broadly. Key Messages: Vepdegestrant marks the transition of PROTAC technology from experimental pharmacology to approved cancer treatment. Its phase III benefit in ESR1-mutated but not biomarker-unselected ER-positive disease reinforces ESR1 as an actionable resistance biomarker and demonstrates that successful protein degradation remains dependent on biological context. The next phase of precision endocrine therapy will likely be defined by treatment timing, serial molecular monitoring, rational combinations, and resistance biology rather than by a single universally preferred ER degrader.
No takes yet. Share an insight, caveat, or question.
Alkhanafsa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: